Affiliation:
1. Key Laboratory of Chinese Medicine Compound
and Chinese Medicine Resources Ministry of Education, Hubei University of Chinese Medicine, Wuhan 430065,
China
2. Basic Medical Sciences College, Hubei University of Chinese Medicine, Wuhan 430065, China
3. Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan 430030, China
Abstract
Background:
Wu-Mei-Wan (WMW), a traditional Chinese medicine (TCM) formula,
has a good effect on the treatment of obesity and has been proven helpful to promote the metabolism
of adipose tissue. However, its underlying mechanism remains to be studied. This study aims
to explore the potential pharmacological mechanism of WMW in the treatment of obesity.
Methods:
Network pharmacology was used to sort out the relationship between WMW putative
targets and obesity-related drug targets or disease targets, which indicated the mechanism of
WMW in treating obesity from two aspects of clinical drugs approved by the Food and Drug Administration
(FDA) and obesity-related diseases. Databases such as Traditional Chinese Medicine
Systems Pharmacology (TCMSP), PubChem, DrugBank, DisGeNET, and Genecards were used to
collect information about targets. String platform was used to convert the data into gene symbol of
“homo sapiens”, and perform gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) enrichment analyses. With the Human Protein Reference Database (HPRD) as background
data, Cytoscape 3.6.0 software was used to construct a new protein-protein interaction
(PPI) network. Mechanism diagrams of key pathways were obtained from the KEGG database.
AutoDock Vina software was used to conduct molecular docking verification.
Results:
The number of targets in the overlap between WMW putative targets and obesity-related
drug targets accounted for more than 50% of the latter, and HTR3A, SLC6A4, and CYP3A4 were
core targets. In obesity-related disease targets-WMW putative targets PPI network, the Th17 cell
differentiation pathway, and the IL-17 signaling pathway were key pathways, and the 1st module
and the 7th module were central function modules that were highly associated with immunity and
inflammation. Molecular docking verified that STAT3, TGFB1, MMP9, AHR, IL1B, and CCL2
were core targets in the treatment of WMW on obesity.
Conclusion:
WMW has similar effects on lipid and drug metabolism as the current obesity-related drugs,
and is likely to treat obesity by inhibiting Th17 cell differentiation and alleviating metabolic inflammation.
Funder
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine
Reference36 articles.
1. Sung H.; Siegel R.L.; Torre L.A.; Pearson-Stuttard J.; Is-lami F.; Fedewa S.A.; Goding Sauer A.; Shuval K.; Gapstur S.M.; Jacobs E.J.; Giovannucci E.L.; Jemal A.; Global pat-terns in excess body weight and the associated cancer burden. CA Cancer J Clin 2019,69(2),88-112
2. Wu F.; Yang X.; Hu M.; Shao Q.; Fang K.; Li J.; Zhao Y.; Xu L.; Zou X.; Lu F.; Chen G.; Wu-Mei-Wan prevents high-fat diet-induced obesity by reducing white adipose tissue and enhancing brown adipose tissue function. Phytomedicine 2020,76,153258
3. Yang X.; Lu F.; Li L.; Li J.; Luo J.; Zhang S.; Liu X.; Chen G.; Wu-Mei-wan protects pancreatic β cells by inhibit-ing NLRP3 Inflammasome activation in diabetic mice. BMC Complement Altern Med 2019,19(1),35
4. Yang X.; Li L.; Fang K.; Dong R.; Li J.; Zhao Y.; Dong H.; Yi P.; Huang Z.; Chen G.; Lu F.; Wu-Mei-Wan reduces insulin resistance via inhibition of NLRP3 inflammasome ac-tivation in HepG2 cells. Evid Based Complement Alternat Med 2017,2017,7283241
5. Hopkins A.L.; Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008,4(11),682-690
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Acne Comorbidities;Clinical, Cosmetic and Investigational Dermatology;2022-11